Albert Labs appoints Dr. Sara Tai, Senior Lecturer in Clinical Psychology from Manchester University as Principal Investigator for our upcoming Real-World Evidence Study on our natural psilocybin medicine, KRN-101. The trial will evaluate the safety and efficacy of KRN-101, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America.
In this video, we speak with Dr. Sara Tai about her research background and what brought her to Albert Labs.
© 2023 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact [email protected]